Paper Details

  1. Home
  2. Paper Details

Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.

Author: BonifácioMaria João, KitajimaTakashi, MizoteShintaro, MoserPaul, Soares-da-SilvaPatrício, TanakaMakoto, UmemuraTakeo, YonedaKazuhiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Opicapone, a third-generation COMT inhibitor, demonstrated sustained and dose-dependent COMT inhibition after repeated administration, despite being rapidly eliminated from plasma.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The aim of the study was to clarify the dose response for inhibition of catechol-O-methyltransferase (COMT) by opicapone, a third generation COMT inhibitor, after acute and repeated administration to the cynomolgus monkey with pharmacokinetic evaluation at the higher dose. METHODS: Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.neuropharm.2018.10.001

データ提供：米国国立医学図書館（NLM）

Opicapone: A Potential Game-Changer for Parkinson's Disease

The world of neurology is constantly searching for better treatments for Parkinson's disease. This study investigates the effectiveness of [specific drug] as a catechol-O-methyltransferase (COMT) inhibitor for improving levodopa bioavailability in patients with Parkinson's disease. The researchers [study design] to assess the impact of [specific drug] on COMT activity in a [animal model] . Their findings suggest that [specific drug] may be a potent and long-lasting COMT inhibitor with potential benefits for managing Parkinson's disease. This study provides valuable insights for clinicians and researchers seeking to improve treatment strategies for this complex neurodegenerative condition.

Opicapone: A Potent and Long-Lasting COMT Inhibitor

This research highlights the potential of opicapone as a potent and long-lasting COMT inhibitor. The study found that [specific result], demonstrating the drug's ability to significantly reduce COMT activity in a [animal model] . These findings suggest that opicapone may be a promising therapeutic agent for improving levodopa bioavailability in patients with Parkinson's disease.

Managing Parkinson's Disease: A Multifaceted Approach

This research underscores the importance of a multifaceted approach to managing Parkinson's disease. The findings suggest that [specific recommendation] could potentially improve patient outcomes. It's a reminder that addressing neurodegenerative conditions requires a combination of medication, therapy, and lifestyle modifications.

Dr.Camel's Conclusion

This research provides encouraging evidence for the potential of opicapone as a novel therapeutic for Parkinson's disease. The study highlights the importance of developing new and effective treatment options to address the unmet needs of patients with this debilitating condition.

Date :
  1. Date Completed 2019-02-25
  2. Date Revised 2019-02-25
Further Info :

Pubmed ID

30290160

DOI: Digital Object Identifier

10.1016/j.neuropharm.2018.10.001

Related Literature

Article Analysis
・Effects of opicapone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.